[TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE]

Area of Science:

• Ophthalmology
• Immunology

Background:

• Dry eye disease is a common ocular disorder affecting 5-50% of the population.
• Core mechanisms include ocular surface inflammation and hyperosmolarity.
• Tear composition changes involve pro-inflammatory mediators and cell damage.

Purpose of the Study:

• To provide an updated review of anti-inflammatory agents for dry eye disease.
• To highlight recent therapeutic advancements and mechanisms of action.

Main Methods:

• Literature review of anti-inflammatory treatments for dry eye.
• Analysis of mechanisms involving inflammation, hyperosmolarity, and cell damage.
• Discussion of approved and emerging therapeutic agents.

Main Results:

• Established anti-inflammatory agents include corticosteroids, immunomodulators, and essential fatty acids.
• Lifitegrast, an LFA-1 antagonist, represents a novel therapeutic approach.
• Lifitegrast targets ICAM-1 binding to LFA-1, reducing inflammation.

Conclusions:

• Effective management of dry eye requires addressing underlying inflammation and hyperosmolarity.
• Lifitegrast offers a new targeted therapy for dry eye by modulating immune cell interactions.
• Continued research into anti-inflammatory mechanisms is crucial for developing improved dry eye treatments.